Description: Redwood Pharma AB engages in the development of ophthalmic drugs for medical needs in Sweden. Its lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women; and RP501, a next generation smart hydrogel medical device for the treatment of mild dry eye. The company was founded in 2012 and is headquartered in Stockholm, Sweden.
Home Page: www.redwoodpharma.se
Ringvägen 100E
Stockholm,
118 60
Sweden
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Ulf Bjorklund M.Sc. | Chairman & Chief Medical Officer |
| Mr. Martin Vidaeus M.B.A., MBA | Founder, CEO & Director |
| Mr. Hans Ageland MSEng | Founder & COO |
| Mr. Peter Rooslien B.A., BA | Chief Financial Officer |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.0759 |
| Price-to-Book MRQ: | 0.3087 |
| Price-to-Sales TTM: | 115.0924 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1 |